NEW YORK (TheStreet) -- UBS upgraded Allergan (AGN) to "buy" from "neutral" and set a $200 price target. The firm said the company plans to see more sales growth while they consider a deal with Valeant (VRX).
Leerink Swann also increased its price target on Allergan to $184, increased its estimates and set a "market perform" rating. The firm said the company is aggressively cutting costs.
The stock closed at $171.14 on Monday.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. AGN data by YCharts
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts